Trial · NCT03632317
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
NCT03632317, Phase 2, Withdrawn, University of Michigan Rogel Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas. Trials, record NCT03632317. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03632317
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
- NCT number
- NCT03632317
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Conditions
- Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Panobinostat, Everolimus
- First posted
- 2018-08-15
- Last updated
- 2019-08-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Progression Free Survival (PFS) at 1 Year | 1year | Median PFS at 1 year for stratum A will be measured. Progression is defined as \> 25% increase in the size of the tumor or appearance of new lesions. |
| Primary | Median Progression Free Survival (PFS) at 2 Years | 2years | Median PFS at 1 year for stratum A will be measured. Progression is defined as \> 25% increase in the size of the tumor or appearance of new lesions. |
| Primary | Overall Survival at 1Year | 1year | The proportion of patients alive at 1 year for stratum A. |
| Primary | Overall Survival at 2Years | 2years | The proportion of patients alive at 2 years for stratum A. |
| Primary | Overall Response Rate (ORR) After Two Cycles of Panobinostat + Everolimus | 84 Days | Overall Response Rate (ORR) After Two Cycles of Panobinostat + Everolimus for stratum B. Overall response is defined as a partial or complete response. Partial response is defined as a ≥50% decrease in size of tumor in comparison to baseline measurements. Complete response is defined as the disappearance of all abnormal signal. This includes return to normal size of the brainstem for brainstem lesions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03632317
GET https://conductscience.org/api/trials/v1/NCT03632317/registered